Xoma Corp. Company Profile (NASDAQ:XOMA)

About Xoma Corp.

Xoma Corp. logoXOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: XOMA
  • CUSIP: 98419J10
Key Metrics:
  • Previous Close: $0.58
  • 50 Day Moving Average: $0.5842
  • 200 Day Moving Average: $0.6998
  • Trailing P/E Ratio: 52.9636
  • Foreward P/E Ratio: -1.21
  • P/E Growth: -0.0600
  • Market Cap: $70.25M
  • Outstanding Shares: 120,583,000
  • Beta: 2.63
Additional Links:
Companies Related to Xoma Corp.:

Analyst Ratings

Consensus Ratings for Xoma Corp. (NASDAQ:XOMA) (?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $2.08 (256.16% upside)

Analysts' Ratings History for Xoma Corp. (NASDAQ:XOMA)
Show:
DateFirmActionRatingPrice TargetDetails
8/10/2016Cowen and CompanyReiterated RatingNeutralView Rating Details
8/5/2016Jefferies GroupReiterated RatingHoldView Rating Details
3/12/2016Piper Jaffray Cos.Reiterated RatingHoldView Rating Details
3/11/2016Royal Bank Of CanadaReiterated RatingSector Perform$2.00View Rating Details
3/11/2016WedbushReiterated RatingOutperform$6.00 -> $3.00View Rating Details
9/15/2015Deutsche Bank AGReiterated RatingSellView Rating Details
7/22/2015Ladenburg ThalmannDowngradeBuy -> NeutralView Rating Details
6/29/2015SusquehannaDowngradePositive -> NeutralView Rating Details
5/5/2015Credit Suisse Group AGReiterated RatingNeutral$5.00View Rating Details
10/10/2014Roth CapitalInitiated CoverageBuy$9.00View Rating Details
(Data available from 8/30/2014 forward)

Earnings

Earnings History for Xoma Corp. (NASDAQ:XOMA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/3/2016($0.12)($0.13)$0.84 million$0.40 millionViewN/AView Earnings Details
5/4/2016($0.12)($0.07)ViewN/AView Earnings Details
3/9/2016Q415($0.15)$0.21$4.01 million$48.18 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.18)$3.55 million$2.10 millionViewListenView Earnings Details
8/6/2015Q215($0.18)($0.20)$4.38 million$2.54 millionViewListenView Earnings Details
5/7/2015Q115($0.16)($0.19)$4.31 million$2.65 millionViewListenView Earnings Details
3/11/2015Q414($0.14)($0.12)$10.70 million$4.30 millionViewN/AView Earnings Details
11/6/2014Q314($0.17)($0.17)$7.00 million$5.10 millionViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)$5.32 million$5.97 millionViewListenView Earnings Details
5/7/2014Q114($0.17)($0.23)$7.40 million$3.41 millionViewN/AView Earnings Details
3/4/2014Q413($0.19)($0.55)$7.92 million$8.45 millionViewN/AView Earnings Details
11/7/2013Q313($0.18)($0.21)$7.87 million$6.31 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.21)$9.30 million$7.20 millionViewN/AView Earnings Details
11/7/2012Q312($0.21)($0.39)$11.69 million$7.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Xoma Corp. (NASDAQ:XOMA)
Current Year EPS Consensus Estimate: $-0.46 EPS
Next Year EPS Consensus Estimate: $-0.48 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.10)($0.10)($0.10)
Q2 20162($0.15)($0.09)($0.12)
Q3 20162($0.14)($0.10)($0.12)
Q4 20162($0.14)($0.12)($0.13)
Q1 20171($0.12)($0.12)($0.12)
Q2 20171($0.13)($0.13)($0.13)
Q3 20171($0.13)($0.13)($0.13)
Q4 20171($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Xoma Corp. (NASDAQ:XOMA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Xoma Corp. (NASDAQ:XOMA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/22/2016John VarianCEOSell81,022$0.78$63,197.16View SEC Filing  
3/22/2016Patrick J Md Phd ScannonVPSell14,785$0.78$11,532.30View SEC Filing  
3/22/2016Paul D RubinCMOSell24,194$0.78$18,871.32View SEC Filing  
2/1/2016Patrick J Md Phd ScannonVPSell8,000$1.01$8,080.00View SEC Filing  
12/28/2015Patrick J Md Phd ScannonVPSell8,000$1.37$10,960.00View SEC Filing  
11/23/2015Patrick J Md Phd ScannonVPSell8,000$1.35$10,800.00View SEC Filing  
10/26/2015Patrick J Md Phd ScannonVPSell8,000$1.04$8,320.00View SEC Filing  
7/22/2015Bros. Advisors Lp BakerInsiderSell11,000,000$1.09$11,990,000.00View SEC Filing  
7/15/2015John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
7/15/2015Paul D RubinCMOSell5,000$4.60$23,000.00View SEC Filing  
7/10/2015Paul D RubinCMOSell33,400$4.55$151,970.00View SEC Filing  
6/15/2015John VarianCEOSell10,000$3.64$36,400.00View SEC Filing  
4/15/2015John VarianCEOSell10,000$3.86$38,600.00View SEC Filing  
3/23/2015Paul D RubinCMOSell32,742$3.94$129,003.48View SEC Filing  
3/16/2015John VarianCEOSell10,000$3.72$37,200.00View SEC Filing  
2/2/2015Patrick J Md Phd ScannonVPSell5,000$3.52$17,600.00View SEC Filing  
1/15/2015John VarianCEOSell10,000$3.46$34,600.00View SEC Filing  
1/6/2015Bros. Advisors Lp BakerDirectorSell2,215,400$3.81$8,440,674.00View SEC Filing  
1/2/2015Patrick J Md Phd ScannonVPSell5,000$3.55$17,750.00View SEC Filing  
12/30/2014Bros. Advisors Lp BakerDirectorSell744,000$3.67$2,730,480.00View SEC Filing  
12/19/2014Bros. Advisors Lp BakerDirectorSell1,605,100$4.26$6,837,726.00View SEC Filing  
12/16/2014Bros. Advisors Lp BakerDirectorSell1,033,800$4.46$4,610,748.00View SEC Filing  
12/15/2014John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
12/15/2014Paul D RubinCMOSell1,600$4.63$7,408.00View SEC Filing  
12/9/2014Bros. Advisors Lp BakerDirectorSell392,353$4.62$1,812,670.86View SEC Filing  
12/4/2014Bros. Advisors Lp BakerDirectorSell2,372,206$4.79$11,362,866.74View SEC Filing  
12/1/2014Patrick J Md Phd ScannonVPSell5,000$5.51$27,550.00View SEC Filing  
11/26/2014James R NealVPSell1,678$5.67$9,514.26View SEC Filing  
11/24/2014James R NealVPSell1,032$5.03$5,190.96View SEC Filing  
11/20/2014Paul D RubinCMOSell5,000$4.55$22,750.00View SEC Filing  
11/13/2014Fred KurlandCFOSell8,773$3.89$34,126.97View SEC Filing  
11/13/2014James R NealVPSell4,387$3.89$17,065.43View SEC Filing  
11/13/2014John VarianCEOSell58,844$3.89$228,903.16View SEC Filing  
11/3/2014Patrick J Md Phd ScannonVPSell5,000$4.33$21,650.00View SEC Filing  
10/28/2014Paul D RubinCMOSell5,000$4.57$22,850.00View SEC Filing  
10/15/2014John VarianCEOSell10,000$3.87$38,700.00View SEC Filing  
10/1/2014Patrick J Md Phd ScannonVPSell5,000$4.09$20,450.00View SEC Filing  
9/15/2014John VarianCEOSell10,000$4.56$45,600.00View SEC Filing  
9/15/2014Paul D RubinCMOSell5,000$4.59$22,950.00View SEC Filing  
9/4/2014Paul D RubinCMOSell10,000$4.56$45,600.00View SEC Filing  
9/2/2014Patrick J Md Phd ScannonVPSell5,000$4.31$21,550.00View SEC Filing  
8/18/2014Paul D RubinCMOSell26,748$4.34$116,086.32View SEC Filing  
8/15/2014Fred KurlandCFOSell10,401$4.31$44,828.31View SEC Filing  
8/15/2014John VarianCEOSell64,823$4.30$278,738.90View SEC Filing  
8/15/2014Patrick J Md Phd ScannonVPSell5,871$4.31$25,304.01View SEC Filing  
8/1/2014Patrick J Md Phd ScannonVPSell5,000$3.83$19,150.00View SEC Filing  
7/15/2014John VarianCEOSell10,000$4.03$40,300.00View SEC Filing  
7/1/2014Patrick J Md Phd ScannonVPSell5,000$4.68$23,400.00View SEC Filing  
6/16/2014John VarianCEOSell10,000$4.54$45,400.00View SEC Filing  
6/16/2014Paul D RubinCMOSell11,580$4.54$52,573.20View SEC Filing  
5/28/2014Paul D RubinCMOSell1,785$4.22$7,532.70View SEC Filing  
5/15/2014John VarianCEOSell10,000$3.55$35,500.00View SEC Filing  
4/15/2014John VarianCEOSell10,000$4.06$40,600.00View SEC Filing  
3/18/2014Fred KurlandCFOSell5,915$6.32$37,382.80View SEC Filing  
3/18/2014John VarianCEOSell21,329$6.32$134,799.28View SEC Filing  
3/18/2014Patrick Md Phd ScannonVPSell3,419$6.32$21,608.08View SEC Filing  
3/18/2014Paul RubinCMOSell17,649$6.31$111,365.19View SEC Filing  
3/18/2014Thomas KleinInsiderSell30,965$6.32$195,698.80View SEC Filing  
3/17/2014John VarianCEOSell10,000$6.03$60,300.00View SEC Filing  
2/18/2014John VarianCEOSell10,000$7.55$75,500.00View SEC Filing  
2/18/2014Paul RubinCMOSell6,000$7.55$45,300.00View SEC Filing  
1/21/2014Paul RubinCMOSell6,000$8.27$49,620.00View SEC Filing  
1/15/2014John VarianCEOSell10,000$8.28$82,800.00View SEC Filing  
1/9/2014Patrick Md Phd ScannonVPSell20,000$8.00$160,000.00View SEC Filing  
12/18/2013Paul RubinCMOSell6,000$5.67$34,020.00View SEC Filing  
12/16/2013John VarianCEOSell10,000$5.44$54,400.00View SEC Filing  
12/2/2013Patrick Md Phd ScannonVPSell20,000$6.00$120,000.00View SEC Filing  
11/27/2013Paul RubinCMOSell4,696$4.54$21,319.84View SEC Filing  
11/18/2013Paul RubinCMOSell1,304$4.08$5,320.32View SEC Filing  
11/15/2013John VarianCEOSell64,932$3.95$256,481.40View SEC Filing  
10/15/2013John VarianCEOSell10,000$4.60$46,000.00View SEC Filing  
9/18/2013Paul RubinCMOSell6,000$4.53$27,180.00View SEC Filing  
9/16/2013John VarianCEOSell10,000$4.59$45,900.00View SEC Filing  
8/19/2013Bros. Advisors Lp BakerDirectorBuy2,757,791$3.62$9,983,203.42View SEC Filing  
8/19/2013Paul RubinCMOSell6,000$3.74$22,440.00View SEC Filing  
8/15/2013John VarianCEOSell61,647$3.87$238,573.89View SEC Filing  
8/14/2013Fred KurlandCFOSell7,498$3.86$28,942.28View SEC Filing  
8/14/2013Patrick Md Phd ScannonVPSell6,002$3.86$23,167.72View SEC Filing  
8/14/2013Paul RubinCMOSell10,520$3.86$40,607.20View SEC Filing  
7/18/2013Paul D RubinCMOSell6,000$4.71$28,260.00View SEC Filing  
7/15/2013John VarianCEOSell10,000$4.81$48,100.00View SEC Filing  
5/29/2013Paul D RubinCMOSell1,797$4.16$7,475.52View SEC Filing  
5/20/2013Paul D RubinCMOSell6,000$0.54$3,240.00View SEC Filing  
11/14/2012Fred KurlandCFOSell9,111$2.56$23,324.16View SEC Filing  
11/14/2012John VarianCEOSell40,587$2.56$103,902.72View SEC Filing  
11/14/2012Patrick J Md Phd ScannonEVPSell8,773$2.56$22,458.88View SEC Filing  
10/29/2012Julian BakerDirectorBuy4,722,666$3.00$14,167,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Xoma Corp. (NASDAQ:XOMA)
DateHeadline
finance.yahoo.com logoXOMA CORP Financials (NASDAQ:XOMA)
finance.yahoo.com - August 11 at 9:01 PM
capitalcube.com logoETF’s with exposure to XOMA Corp. : August 11, 2016 (NASDAQ:XOMA)
www.capitalcube.com - August 11 at 9:01 PM
finance.yahoo.com logoXOMA to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:XOMA)
finance.yahoo.com - August 11 at 9:01 PM
News IconChristopher J. Margolin (NASDAQ:XOMA)
www.linkedin.com - August 10 at 11:40 AM
capitalcube.com logoXOMA Corp. :XOMA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 (NASDAQ:XOMA)
www.capitalcube.com - August 9 at 8:43 PM
smarteranalyst.com logoCowen Reiterates Neutral Stance on XOMA Corp (XOMA) as Pipeline Development Early and Uncertain - Smarter Analyst (NASDAQ:XOMA)
www.smarteranalyst.com - August 8 at 8:36 PM
News IconXOMA Corporation: XOMA Reports Second Quarter 2016 … – The Wall Street Transcript (NASDAQ:XOMA)
bloodsugardiabetes.org - August 6 at 10:55 AM
News IconHC Stocks Buzzer: Sanofi SA (ADR) (NYSE:SNY), XOMA Corp (NASDAQ:XOMA) - share market updates (press release) (NASDAQ:XOMA)
sharemarketupdates.com - August 4 at 8:51 PM
reuters.com logoBRIEF-Xoma reports Q2 2016 achievements and financial results (NASDAQ:XOMA)
www.reuters.com - August 4 at 11:40 AM
News IconXOMA Reports Second Quarter 2016 Achievements and Financial … – Yahoo Finance (NASDAQ:XOMA)
bloodsugardiabetes.org - August 4 at 11:40 AM
twst.com logoXOMA Corporation: XOMA Reports Second Quarter 2016 Achievements and Financial Results (NASDAQ:XOMA)
www.twst.com - August 4 at 11:40 AM
sg.finance.yahoo.com logoXoma reports 2Q loss (NASDAQ:XOMA)
sg.finance.yahoo.com - August 3 at 8:46 PM
News IconAnalyst Recommendation Worth Stating Today: XOMA Corp (NASDAQ:XOMA) - The Voice Registrar (NASDAQ:XOMA)
voiceregistrar.com - August 2 at 8:47 PM
News IconHC Stocks in Focus: XOMA Corp (NASDAQ:XOMA) PRA Health ... - share market updates (press release) (NASDAQ:XOMA)
sharemarketupdates.com - August 1 at 8:06 PM
equities.com logoXOMA Corporation (XOMA) Jumps 15.65% on July 29 - Equities.com (NASDAQ:XOMA)
www.equities.com - July 29 at 8:40 PM
equities.com logoXOMA Corporation (XOMA) Jumps 5.38% on July 27 (NASDAQ:XOMA)
www.equities.com - July 28 at 11:45 AM
equities.com logoXOMA Corporation (XOMA) Jumps 5.38% on July 27 - Equities.com (NASDAQ:XOMA)
www.equities.com - July 27 at 8:52 PM
News IconHC Stocks Momentum: XOMA Corp (NASDAQ:XOMA), Inovio Pharmaceuticals Inc (NASDAQ:INO) - share market updates (press release) (NASDAQ:XOMA)
sharemarketupdates.com - July 26 at 8:56 PM
tradecalls.org logoXOMA Corporation (XOMA) Shares are Up 4.89% - Trade Calls (NASDAQ:XOMA)
www.tradecalls.org - July 25 at 8:34 PM
seekingalpha.com logoBuy XOMA Corporation For Its Monoclonal Antibodies To Treat Congenital Hyperinsulinism And Refractory Prolactinoma - Seeking Alpha (NASDAQ:XOMA)
seekingalpha.com - July 25 at 5:37 AM
seekingalpha.com logoBuy XOMA Corporation For Its Monoclonal Antibodies To Treat Congenital Hyperinsulinism And Refractory Prolactinoma (NASDAQ:XOMA)
seekingalpha.com - July 24 at 7:49 PM
News IconXOMA Corporation Therapeutics and Product Pipeline Review H1 2016 (NASDAQ:XOMA)
www.medgadget.com - July 22 at 8:09 PM
equities.com logoXOMA Corporation (XOMA) Jumps 14.93% on July 20 | Equities.com - Equities.com (NASDAQ:XOMA)
www.equities.com - July 21 at 8:44 PM
News IconXOMA Corp (NASDAQ:XOMA) & Gap Inc (NYSE:GPS) Trader's ... - Money News (press release) (NASDAQ:XOMA)
www.newsismoney.com - July 21 at 8:44 PM
News IconWhat's New with Celgene Corporation (NASDAQ:CELG), XOMA Corp (NASDAQ:XOMA)? - Post Registrar (NASDAQ:XOMA)
postregistrar.com - July 21 at 8:44 PM
News IconEMA grants orphan drug designation to XOMA 358 to treat congenital hyperinsulinism (NASDAQ:XOMA)
processandproduction.pharmaceutical-business-review.com - July 21 at 11:13 AM
streetinsider.com logoXOMA's (XOMA) XOMA 358 Granted EMA Orphan Drug Designation as CHI Treatment (NASDAQ:XOMA)
www.streetinsider.com - July 21 at 11:13 AM
rttnews.com logoAVXS Making News For The Right Reasons, ONVO Pushing Ahead, XOMA Rises 14% (NASDAQ:XOMA)
www.rttnews.com - July 21 at 11:12 AM
globenewswire.com logoXOMA Receives Orphan Drug Designation in the European Union for XOMA 358 for Treatment of Congenital Hyperinsulinism (NASDAQ:XOMA)
globenewswire.com - July 20 at 9:30 PM
equities.com logoXOMA Corporation (XOMA) Jumps 14.93% on July 20 (NASDAQ:XOMA)
www.equities.com - July 20 at 9:30 PM
News IconNotable News Buzz: Alibaba Group Holding Ltd (NYSE:BABA), XOMA Corp (NASDAQ:XOMA) - NYSE Journal (press release) (NASDAQ:XOMA)
stockznews.com - July 19 at 9:19 AM
news.cmlviz.com logoXOMA Corporation Realized Volatility Hits Extreme Level - CML News (NASDAQ:XOMA)
news.cmlviz.com - July 16 at 7:35 PM
equities.com logoXOMA Corporation (XOMA) Drops 5.4% on July 13 - Equities.com (NASDAQ:XOMA)
www.equities.com - July 16 at 7:35 PM
fiscalstandard.com logoBroker Outlook For XOMA Corporation (XOMA) - Fiscal Standard (NASDAQ:XOMA)
www.fiscalstandard.com - July 8 at 8:17 PM
News IconXOMA Corporation (XOMA) : Analyst Rating Update - TheFounders Daily (NASDAQ:XOMA)
www.thefoundersdaily.com - July 7 at 8:27 PM
News IconHC Stocks Growth: Keryx Biopharmaceuticals (NASDAQ:KERX), XOMA Corp (NASDAQ:XOMA) - share market updates (press release) (NASDAQ:XOMA)
sharemarketupdates.com - July 5 at 7:57 PM
prnewswire.com logoWhy Investors Love These Biotech's Stocks? - XOMA Corp., Navidea Biopharma, Radius Health, and Cara Therapeutics - PR Newswire (press release) (NASDAQ:XOMA)
www.prnewswire.com - July 5 at 7:57 PM
publicnow.com logoXOMA to Present at the Cantor Fitzgerald Healthcare Conference (NASDAQ:XOMA)
www.publicnow.com - July 5 at 2:31 PM
News IconXoma Corporation (NASDAQ:XOMA) Shorted Shares Decreased By 1.69% - Press Telegraph (NASDAQ:XOMA)
presstelegraph.com - July 3 at 5:37 AM
equities.com logoXOMA Corporation (XOMA) Drops 11.1% on June 30 - Equities.com (NASDAQ:XOMA)
www.equities.com - July 2 at 7:44 PM
equities.com logoXOMA Corporation (XOMA) Drops 11.1% on June 30 (NASDAQ:XOMA)
www.equities.com - July 2 at 10:53 AM
tradecalls.org logoShort Term Price Target on XOMA Corporation (XOMA) - Trade Calls (NASDAQ:XOMA)
www.tradecalls.org - July 1 at 11:03 AM
istreetwire.com logoMovers of most recent trading session: TESARO Inc (NASDAQ:TSRO), XOMA Corp (NASDAQ:XOMA), Exeter Resource ... - iStreetWire (NASDAQ:XOMA)
istreetwire.com - June 30 at 8:35 PM
News IconXOMA Corp (XOMA) Stock Gains Big: Here's Why! - CNA Finance (press release) (NASDAQ:XOMA)
cnafinance.com - June 30 at 8:35 PM
News IconXOMA Corp (XOMA) Stock Gains Big: Here’s Why! (NASDAQ:XOMA)
cnafinance.com - June 30 at 11:01 AM
streetupdates.com logoAnalysts Observing Trading Stocks: Allergan plc. (NYSE:AGN) , XOMA Corporation (NASDAQ:XOMA) - Street Updates (NASDAQ:XOMA)
www.streetupdates.com - June 29 at 8:17 PM
tradecalls.org logoAnalyst Rating Update on XOMA Corporation (XOMA) - Trade Calls (NASDAQ:XOMA)
www.tradecalls.org - June 29 at 11:02 AM
equities.com logoXOMA Corporation (XOMA) Hits New 52-week Low During June 27 Session - Equities.com (NASDAQ:XOMA)
www.equities.com - June 29 at 11:02 AM
smarteranalyst.com logoCompany Update (NASDAQ:XOMA): XOMA Corp Initiates Phase 2 Proof-of-Concept Study of XOMA 213 - Smarter Analyst (NASDAQ:XOMA)
www.smarteranalyst.com - June 29 at 11:02 AM
reuters.com logoBRIEF-Xoma initiates Phase 2 proof-of-concept study of Xoma 213 (NASDAQ:XOMA)
www.reuters.com - June 28 at 8:20 PM

Social

Xoma Corp. (NASDAQ:XOMA) Chart for Tuesday, August, 30, 2016


Last Updated on 8/30/2016 by MarketBeat.com Staff